Detection of PSMA-avid Hematologic Malignancies in Patients Undergoing Prostate Cancer Staging With PSMA-PET Scan
Prostate-specific membrane antigen (PSMA) PET scans have evolved as an essential modality in the diagnosis and staging of prostate cancer. PSMA avidity has been detected in additional non-prostate tissues, the significance of which is still not fully understood. Our case series highlights 4 cases from the Brown Health patient population where non-prostate PSMA avidity was found to represent hematologic malignancy. In 3 of our cases, subsequent biopsy confirmed lymphoma at PSMA-avid sites. In another case, a previously known lymphoma was demonstrated as PSMA-avid on prostate cancer staging PSMA-PET scan. These cases highlight the potential use of PSMA-PET as a diagnostic adjunct in lymphoma and raise questions regarding the possible use of anti-PSMA therapy in these malignancies.
Authors
- Ari Pelcovits (ORCID: https://orcid.org/0000-0002-3354-4499)
- Ryan Snow (ORCID: https://orcid.org/0000-0003-3376-6400)
- Benedito A. Carneiro (ORCID: https://orcid.org/0000-0002-5468-1126)
- Anthony Mega
- Galina Lagos
- Sathwik Madireddy (ORCID: https://orcid.org/0000-0002-6148-6652)
- Kim Amelsberg
Institutions
- John Brown University (US)
- Brown University (US)
Publication Details
- Journal
- Clinical nuclear medicine open.
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1097/nm9.0000000000000059
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00